In vivo efficacy and pharmacokinetics of biapenem in a murine model of ventilator-associated pneumonia with Pseudomonas aeruginosa
详细信息 查看全文
- 作者：Koichi Yamada (12)
Yoshihiro Yamamoto (2)
Katsunori Yanagihara (124) k-yanagi@nagasaki-u.ac.jp
Nobuko Araki (1)
Yosuke Harada (12)
Yoshitomo Morinaga (12)
Koichi Izumikawa (2)
Hiroshi Kakeya (2)
Hiroo Hasegawa (1)
Shigeru Kohno (23)
Shimeru Kamihira (1) - 关键词：Biapenem – Ventilator ; associated pneumonia – Pseudomonas aeruginosa
- 刊名：Journal of Infection and Chemotherapy
- 出版年：2012
- 出版时间：August 2012
- 年：2012
- 卷：18
- 期：4
- 页码：472-478
- 全文大小：517.1 KB
- 参考文献：1. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med. 2000;65:867–903.
2. Livemore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis. 2002;34:634–40.
3. Van Eldere J. Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocominal infections. J Antimicrob Chemother. 2003;51:347–52.
4. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.
5. El Sohl AA, Alhajhusain A. Update on the treatment of Pseudomonas aeruginosa pneumonia. J Antimicrob Chemother. 2009;64:229–38.
6. Ubukata K, Chiba N, Kobayashi R. Comparison of in vitro activity of biapenem with other antimicrobial agents against clinical isolates of Pseudomonas aeruginosa. Chemother Jpn. 2002;50:1–10.
7. Bonfiglio G, Maccarone G, Mezzatesta ML, Privitera A, Carciotto V, Santagati M, et al. In vitro activity of biapenem against recent gram-negative, gram-positive clinical isolates. Chemotherapy. 1997;43:393.
8. Gomi K, Fujimura S, Fuse K, Takane H, Nakao Y, Kariya Y, et al. Antibacterial activity of carbapenems against clinical isolates of respiratory bacterial pathogens in the northeastern region of Japan in 2007. J Infect Chemother. 2010;17:200–6.
9. Raymond NJ, Bremner DA. The in vitro activity of biapenem against 964 clinical isolates of aerobic bacteria. J Antimicrob Chemother. 1995;35:681–6.
10. Fukazawa M, Sumita Y, Harabe ET, Tanio T, Nouda H, Kohzuki T, et al. Stability of meropenem and effect of 1β-methyl substitution on its stability in the presence of renal dehydropeptidase I. Antimicrob Agents Chemother. 1992;36:1577–9.
11. Yang Y, Testa RT, Bhachech N, Rasmussen BA, Bush K. Biochemical characterization of novel tetrahydrofuranyl 1β-methylcarbapenems: stability to hydrolysis by renal dehydropeptidases and bacterial β-lactamase, binding to penicillin binding proteins and permeability properties. Antimicrob Agents Chemother. 1999;43:2904–9.
12. Takata T, Aizawa K, Shimizu A, Sakakibara S, Watabe H, Totsuka K. Optimization of dose and dose regimen of biapenem based on pharmacokinetic and pharmacodynamic analysis. J Infect Chemother. 2004;10:76–85.
13. Kaneko Y, Yanagihara K, Kuroki M, Ohi H, Kakeya H, Miyazaki Y, et al. Effects of parenterally administered ciprofloxacin in a murine model of pulmonary Pseudomonas aeruginosa infection mimicking ventilator-associated pneumonia. Chemotherapy. 2001;47:421–9.
14. Sumita Y, Nouda H, Tada H, Kohzuki T, Kato M, Okuda T, et al. Pharmacokinetics of meropenem, a new carbapenem antibiotic, parenterally administered to laboratory animals. Chemotherapy (Tokyo). 1992;40(suppl 1):S123–31.
15. Yamashita N, Kawashima K, Nomura K, Takeuchi H, Hikida M, Naruke T. Pharmacokinetics of biapenem in laboratory animals. Chemotherapy (Tokyo). 1994;42(suppl 1):S243–50.
16. Iaconis JP, Pitkin DH, Sheikh W, Nadler HL. Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials. Clin Infect Dis. 1997;24(suppl 2):S191–6.
17. Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland TR, Sahn DF. Surveillance of antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998–2001. Antimicrob Agents Chemother. 2003;47:1681–8.
18. Zilberberg MD, Chen J, Mody SH, Ramsey AM, Shorr AF. Imipenem resistance of Pseudomonas in pneumonia: a systemic literature review. BMC Pulm Med. 2010;10:45.
19. Kropp H, Sundelof JG, Hajdu R, Kahan FM. Matabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase. Antimicrob Agents Chemother. 1982;22:62–70.
20. Hikida M, Kawashima K, Yoshida M, Mithuhashi S. Inactivation of new carbapenem antibiotics by dehydropeptidase-I from porcine and human renal cortex. J Antimicrob Chemother. 1992;30:129–34.
21. Byers J, Sole M. Analysis of factors related to the development of ventilator-associated pneumonia: use of existing databases. Am J Crit Care. 2000;9:344–9.
22. Craig WA, Ebert SC. Continuous infusion of β-lactam antibiotics. Antimicrob Agents Chemother. 1992;36:2577–83.
23. Sasaki K, Arai T. In vitro postantibiotic effect of biapenem, a new carbapenem antibiotic. Chemotherapy (Tokyo). 1994;42:108–14.
24. Morinaga Y, Yanagihara K, Nakamura S, Yamamoto K, Izumikawa K, Seki M, et al. In vivo efficacy and pharmacokinetics of tomopenem (CS-023), a novel carbapenem, against Pseudomonas aeruginosa in a murine chronic respiratory tract infection model. J Antimicrob Chemother. 2008;62:1326–31. - 作者单位：1. Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501 Japan2. Second Department of Internal Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan3. Global COE Program, Nagasaki University, Nagasaki, Japan4. Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501 Japan
- ISSN：1437-7780
文摘
Biapenem (BIPM) has high bactericidal activity against Pseudomonas aeruginosa and similar activity in vitro as meropenem (MEPM). We used a murine model to examine the efficacy of biapenem against ventilator-associated pneumonia (VAP) caused by P. aeruginosa. Mice were treated by intraperitoneal injection with 100 mg/kg BIPM or MEPM every 12 h beginning 12 h after inoculation with P. aeruginosa. Survival was evaluated for 7 days, and 24 h after infection, lung histopathology was analyzed and the number of viable bacteria in the lungs and blood was counted. In addition, the pharmacokinetics of BIPM and MEPM were analyzed after the initial treatment. BIPM and MEPM significantly prolonged survival compared to control (P < 0.05). The lungs of mice treated with BIPM or MEPM had significantly fewer viable bacteria (3.54 ± 0.28 vs. 3.77 ± 0.14 log10 CFU/ml) than in the lungs of control mice (6.65 ± 0.57 log10 CFU/ml) (P < 0.05). Furthermore, viable bacteria were not detected in the blood of mice treated with BIPM or MEPM (control 2.85 ± 0.85 log10 CFU/ml) (P < 0.05). Histopathological examination of lung specimens indicated that BIPM and MEPM prevent the progression of lung inflammation, including alveolar neutrophil infiltration and hemorrhage. The % time above MIC for BIPM and MEPM was 15.4% and 18.3% in plasma and 19.8% and 19.8% in lungs, respectively. These results show that BIPM and MEPM significantly prolongs survival and reduces the number of viable bacteria in a murine model of VAP caused by P. aeruginosa. Therefore, BIPM might be a potent and effective treatment for VAP caused by this bacterium.